Timing of lung immune responses defines tuberculosis protection

Tuberculosis remains a leading infectious killer, but the immune mechanisms that truly protect the lung from Mycobacterium tuberculosis (Mtb) are still not fully understood. To dig into what separates a contained infection from one that progresses, researchers led by Fergal J. Duffy used single-cell RNA sequencing to examine immune cells directly in the lungs. They compared naïve mice with mice that had a model of naturally acquired resistance called contained Mtb infection (CoMtb). Importantly, the team sampled across multiple time points and used different mouse strains and Mtb strains to capture the evolving biology after aerosol infection. By profiling individual lung immune cells over time, the researchers sought immune correlates associated with protection — the patterns of cells and signals that tip the balance toward control rather than disease. This approach allowed them to watch not just which cell types were present, but how those cells changed their activity, communicated with one another, and resolved after challenge, offering a dynamic view of lung immunity against Mtb.

Using single-cell RNA sequencing of lung immune cells after aerosol Mtb infection, the study mapped the timing and character of cellular responses that distinguish protected from susceptible animals. Protection in CoMtb mice was marked by rapid, transient recruitment and activation of CD4 ⁺ T cells, macrophages, NK, and NKT cells early after challenge. These early responses included short-lived bursts of type I and II interferon signaling, increased oxidative phosphorylation, and enhanced chemokine-mediated cell-cell communication. By contrast, primary infection produced delayed but sustained interferon and neutrophil responses and resulted in higher bacterial burdens. The authors also compared those transcriptional patterns with data from nonhuman primates given intravenous BCG vaccination and found overlapping features, including enrichment of activated tissue-resident CD4 ⁺ T cells and innate effector populations. Together, the methods and results emphasize not merely which cell types appear, but when they activate and how their signals are coordinated across the lung.

These findings argue for a shift in how we think about protective immunity to Mtb: effective defense appears to depend on the timing and coordination of multiple immune pathways rather than the magnitude of any single response. The transient, well-timed early activation and resolution seen in CoMtb mice points to a balanced program of recruitment, activation, and metabolic activity—for example, oxidative phosphorylation—that contains bacteria without provoking prolonged inflammation. The overlap with responses seen after intravenous BCG vaccination in nonhuman primates suggests that vaccine strategies could aim to reproduce these protective lung immune dynamics, enriching activated tissue-resident CD4 ⁺ T cells and innate effectors at the right moment. By offering a dynamic blueprint of protective lung immunity, this work provides a framework for designing vaccines and interventions that steer the immune response toward coordinated, timely protection against tuberculosis.